Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

Pfizer (PFE) announced on Thursday that its cancer drug regimen, Talzenna plus Xtandi, met the primary endpoint in a Phase 3 trial for a new indication in prostate cancer. Xtandi, marketed by Pfizer ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an ARP inhibitor. The ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

Genetic testing, including germline and somatic, is vital for prostate cancer prognosis and personalized treatment strategies. PARP inhibitors, targeting BRCA mutations, are a promising therapy for ...

Analysis of data from a large patient population revealed a lower survival rate for men with prostate cancer (PCa) and depression compared with those without depression as well as healthy controls, ...

The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in Nature Communications, by a multidisciplinary team ...

A new study sheds light on why promising cancer treatments can produce dramatically different results across patients.

Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...